TICKERNERD
Menu
BLSMHealthcare · Biotechnology

BLSM Stock Forecast: Blossomhill Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$17
+1.63% on the day

The 5 Wall Street analysts covering Blossomhill Therapeutics, Inc. hold a median 12-month price target of $35 — +107.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 8 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$536.5M
Ticker Nerd rank
0 / 100
Median analyst target
$35
Analysts covering
5
Total return, dividends reinvested
1W
−9.2%
1M
−26.4%
From high
−37.1%
From low
+6.8%
$16
$27
Range since 7 Aug 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

BLSM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Blossomhill Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
0 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
52
Revisions
27
Value
13
Growth
8
Accruals
8
Quality
2
Momentum
1
Issuance
0
Volatility
0

Size (52): Smaller than most of the companies we track.

Volatility (0): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BLSM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BLSM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 7 Aug 2026Adjusted close, US dollars
$15$20$25$30$35$40Sep 26Oct 26BLSMHigh $40Median $35Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $30Median $35High $40

The green dot is the last close — the median target sits +107.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Sept 2026GuggenheimMaintainsBuy$30 → $40
21 Sept 2026Leerink PartnersMaintainsOutperform$36 → $40
1 Sept 2026GuggenheimInitiatesBuy$30
1 Sept 2026GuggenheimInitiatesBuy—
1 Sept 2026HC Wainwright & Co.InitiatesBuy$35
1 Sept 2026HC Wainwright & Co.InitiatesBuy—
1 Sept 2026JP MorganInitiatesOverweight$28
1 Sept 2026JP MorganInitiatesOverweight—
1 Sept 2026Leerink PartnersInitiatesOutperform—
1 Sept 2026LifeSci CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BLSM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BLSM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

BLSM vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180Sep 26Oct 26BLSMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BLSM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Blossomhill Therapeutics, Inc. (BLSM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.1×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
−3.2×

Cheaper than 96% of US stocks

EV / EBITDA
−8.5×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
46.0%

Higher than 92% of US stocks

Return on assets
−37.2%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Blossomhill Therapeutics, Inc. (BLSM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Blossomhill Therapeutics, Inc. has a market value of $536.5M and an enterprise value of $721.3M.

  • Shares outstanding: 29.1M.

  • Trailing P/E: −8.1×; forward P/E: −4.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Blossomhill Therapeutics, Inc. employs 69 people.

market figures as at 9 Oct 2026

Data provided by Twelve Data

Peers

BLSM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BLSMBlossomhill Therapeutics, Inc.$536.5M
0
CBIOCrescent Biopharma, Inc.$521.9M
60
NGNENeurogene, Inc.$511.5M
58
CTNMContineum Therapeutics, Inc.$510.8M
49
MPLTMapLight Therapeutics, Inc.$508.5M
12
PBYIPuma Biotechnology, Inc.$507.4M
92
RGNXREGENXBIO, Inc.$528.4M
49

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Blossomhill Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BLSM news & analysis

BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer

GlobeNewsWire · 28 Sept 2026positive

BlossomHill Therapeutics presented preclinical data on its novel pan-KRAS inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer. The data showed prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting continued advancement toward an IND submission in Q1 2027.

Why it matters — The encouraging preclinical results and planned IND submission timeline signal progress for a key pipeline candidate in BlossomHill's development efforts.

BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 18 Sept 2026positive

BlossomHill Therapeutics reported its second quarter 2026 financial results, noting the successful completion of an upsized $168.3 million initial public offering that strengthened its balance sheet. The company also announced that the FDA granted Fast Track designation to BH-30643 for the treatment of advanced EGFR C797S-positive non-small cell lung cancer.

Why it matters — A BLSM watcher would care because the strengthened capital position and FDA Fast Track designation for BH-30643 mark notable progress for a clinical-stage oncology company.

BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer

GlobeNewsWire · 15 Sept 2026positive

BlossomHill Therapeutics presented updated data from the ongoing Phase 1/2 SOLARA trial of its OMNI-EGFR inhibitor BH-30643 in EGFR C797S-positive non-small cell lung cancer at the IASLC 2026 World Conference on Lung Cancer, reporting a 45% objective response rate and 88% disease control rate, along with a favorable safety profile. The presentation followed the company's receipt of FDA Fast Track designation for the drug in this indication.

Why it matters — The updated efficacy and safety data from the SOLARA trial, combined with the previously granted FDA Fast Track designation, highlight BH-30643's potential progress in a difficult-to-treat NSCLC population with no approved targeted therapies.

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 3 Sept 2026neutral

BlossomHill Therapeutics, a clinical-stage biopharmaceutical company developing small molecule cancer medicines, announced it will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. The presentations were announced via a company press release on September 3, 2026.

Why it matters — A BLSM watcher would care because the company's participation in these industry and investor conferences provides opportunities to present its RAS-targeted science and engage with the investment community.

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

GlobeNewsWire · 1 Sept 2026positive

BlossomHill Therapeutics announced it will present updated data from the ongoing Phase 1/2 SOLARA trial of its macrocyclic OMNI-EGFR inhibitor BH-30643, describing anti-tumor activity in patients with secondary EGFR resistance mutations such as EGFR C797S. The data will be delivered as a mini-oral presentation on September 15, 2026, at the World Conference on Lung Cancer in Seoul. The company also noted that BH-30643 recently received FDA Fast Track designation for C797S-positive resistance in EGFR-mutant NSCLC.

Why it matters — A BLSM watcher would care because this presentation showcases progress on its lead candidate BH-30643 in a setting where no oral targeted therapies are approved, and the Fast Track designation reflects regulatory momentum for the program.

FAQ

Frequently asked questions about BLSM stock

What is the BLSM stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Blossomhill Therapeutics, Inc. have a median 12-month price target of $35, with estimates ranging from $30 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BLSM stock a buy right now?

Of the 5 analysts covering Blossomhill Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Blossomhill Therapeutics, Inc. 0 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BLSM?

As at 8 Oct 2026, Blossomhill Therapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (52 of 100).

Will BLSM stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +107.3% from the last close, and Ticker Nerd's factor model ranks Blossomhill Therapeutics, Inc. 0 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BLSM stock forecast for 2030?

No analyst covering Blossomhill Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BLSM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $40 over the next 12 months.

What does Blossomhill Therapeutics, Inc. do?

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for cancer treatment.

What is the latest news on BLSM?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer". BlossomHill Therapeutics presented preclinical data on its novel pan-KRAS inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer. The data showed prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting continued advancement toward an IND submission in Q1 2027.

Company

About Blossomhill Therapeutics, Inc.

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule medicines for cancer treatment. The company applies a chemistry-based approach to design investigational therapies aimed at addressing unmet medical needs in oncology. Its current pipeline includes programs for EGFR-mutant non-small cell lung cancer, relapsed or refractory acute myeloid leukemia, and higher-risk myelodysplastic syndromes, reflecting a focus on difficult-to-treat blood and solid tumors. BlossomHill Therapeutics also advances preclinical candidates targeting pathways relevant to cancer biology, including KRAS-driven disease. Headquartered in San Diego, California, BlossomHill Therapeutics operates within the biotechnology sector and centers its work on drug discovery and clinical development.

CEO Dr. Jingrong Jean Cui Ph.D. · 69 employees · United States · https://bhtherapeutics.com